Digoxin Management in HFrEF Patients Undergoing Coronary Angiography

Introduction to Digoxin Management

The American Heart Association, American College of Cardiology, and Heart Failure Society of America recommend continuing digoxin in patients with HFrEF already taking it, without interruption, through coronary angiography, as withdrawal can precipitate clinical worsening of heart failure 1, 2
The American College of Cardiology suggests that digoxin does not cause hypotension, which is advantageous in the periprocedural setting, although this particular fact is from Praxis Medical Insights, an alternative source states that digoxin has no significant hemodynamic effects 3

The American Heart Association, American College of Cardiology, and Heart Failure Society of America explicitly state that clinical worsening after withdrawal of digoxin has been shown, making discontinuation before CAG potentially harmful 1, 2
The American College of Cardiology assigns digoxin a Class 2b recommendation (Level B-R evidence) for patients with HFrEF, meaning it "might be considered" only after guideline-directed medical therapy optimization, indicating that initiation of digoxin specifically for coronary angiography is not recommended 1, 4, 2

The landmark DIG trial showed that digoxin reduces heart failure hospitalizations by 28% but has no effect on mortality, providing evidence of its efficacy in certain contexts 5, 6
Modern evidence suggests that digoxin's benefit is uncertain in patients already on contemporary guideline-directed medical therapy, highlighting the need for careful consideration in its use 1, 2

The European Heart Journal notes that contrast-induced nephropathy from CAG can significantly alter digoxin clearance and increase toxicity risk, emphasizing the importance of monitoring renal function 5
The European Heart Journal and Praxis Medical Insights recommend checking potassium and magnesium levels before CAG in all patients on digoxin and maintaining potassium >4.0 mEq/L and magnesium >2.0 mg/dL throughout the periprocedural period to minimize toxicity risk 5, 3

The American College of Cardiology recommends verifying the digoxin dose is appropriate for the patient's renal function and maintaining target serum concentrations of 0.5-0.9 ng/mL, with standard maintenance dosing being 0.125-0.25 mg daily for patients <70 years with normal renal function 1, 6, 3
Serum digoxin levels ≥1.2 ng/mL are associated with significantly higher mortality risk, underscoring the importance of careful dosing and monitoring 1, 2

In patients with both HFrEF and atrial fibrillation, the European Heart Journal suggests that digoxin continuation is particularly important for rate control during the periprocedural period, as it provides rate control without lowering blood pressure 5, 3
The European Society of Cardiology gives a Class I recommendation (Level C evidence) for digoxin use in atrial fibrillation with left ventricular ejection fraction <40% for rate control, supporting its use in this specific population 5